Conference Coverage: ASCO 2024 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
FACULTY MEMBERS
Marina Garassino, MD
University of Chicago, IL, USA
Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, USA
Ignacio Wistuba, MD
MD Anderson Cancer Center, Houston, TX, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France
Solange Peters, MD, PhD
University of Lausanne, Switzerland
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Small Cell Lung Cancer
- Targeted Therapy in Stage I–III NSCLC
- Oncogene-Driven, Stage IV NSCLC: EGFR/HER2
- Oncogene-Driven, Stage IV NSCLC: KRAS, MET, ALK
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC
